Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 6:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,914 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PET Scanning Clear all
Terminated Phase 1 Interventional Results available

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

NCT05035407
View directory record Official record
Conditions
Kita-kyushu Lung Cancer Antigen 1, Human
Interventions
IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR, Fludarabine, EKG, CXR, CT, MRI, PET, Biopsy, Acetaminophen, Ondansetron, Meperidine, Indomethacin, Famotidine
Drug · Biological · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 27, 2026, 6:38 PM EDT
Completed Not applicable Interventional Results available

PET/MRI and PET/CT in Diagnosing Younger Patients With Cancer

NCT02287636
View directory record Official record
Conditions
Childhood Cancer
Interventions
fludeoxyglucose F 18, positron emission tomography, computed tomography, magnetic resonance imaging
Radiation · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 27, 2026, 6:38 PM EDT
Recruiting Phase 1 Interventional

huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma

NCT07343934
View directory record Official record
Conditions
Relapsed or Refractory Follicular Lymphoma
Interventions
huCART19-IL18-eDHFR cells, [18F]Fluoropropyl-Trimethoprim
Biological · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2042
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 27, 2026, 6:38 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Imaging of CB1 Receptors Using (11C)SD5024

NCT01399398
View directory record Official record
Conditions
Healthy
Interventions
Brain Scan-PET, Brain Scan-MRI, Arterial Line, Venous Line, Blood Sampling
Procedure
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 27, 2026, 6:38 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers

NCT02683824
View directory record Official record
Conditions
Healthy Subject, Pancreatic Carcinoma
Interventions
Computed Tomography, Laboratory Biomarker Analysis, PET/MRI scan, [18F]FP-R01-MG-F2
Diagnostic Test · Other · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 27, 2026, 6:38 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls

NCT03675282
View directory record Official record
Conditions
Parkinson Disease, REM Sleep Behavior Disorder, Healthy
Interventions
(11C)PE2I, Ioflupane
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
20 Years to 100 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 27, 2026, 6:38 PM EDT
Active, not recruiting Not applicable Interventional

PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study

NCT01266096
View directory record Official record
Conditions
Newly Diagnosed or Recurrent Metastatic Melanoma Patients, Malignant Brain Tumors
Interventions
PET scan with 124I-cRGDY-PEG-dots
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 27, 2026, 6:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Combined Electroencephalogram, Magnetic Resonance Imaging-Positron Emission Tomography of Dexmedetomidine Induced Sleep

NCT01485380
View directory record Official record
Conditions
Dexmedetomidine Induced Sedation
Interventions
dexmedetomidine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 27, 2026, 6:38 PM EDT
Terminated No phase listed Observational

Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging

NCT00499382
View directory record Official record
Conditions
Advanced Cancers
Interventions
Nuclear Medicine Cardiac Scan, PET/CT Cardiac Scan
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 27, 2026, 6:38 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

FDG PET/MR Imaging of Peripheral Pain Generators

NCT06171659
View directory record Official record
Conditions
Pain, Nociceptive Pain
Interventions
FDG radiotracer, PET/MRI, PET/CT imaging
Drug · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 85 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 27, 2026, 6:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Brain Imaging and Retreatment Study of Persistent Lyme Disease

NCT00037479
View directory record Official record
Conditions
Lyme Disease, Lyme Neuroborreliosis
Interventions
ceftriaxone
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2005 · Synced Oct 27, 2026, 6:38 PM EDT
Recruiting Phase 2 Interventional

Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

NCT05830058
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm, Melanoma, Renal Cell Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Other · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 27, 2026, 6:38 PM EDT
Terminated Phase 2 Interventional Results available

11C-acetate for Treatment Response After Radiotherapy for HCC

NCT02549755
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
11C-Acetate
Drug
Lead sponsor
Justin Sims
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 22, 2017 · Synced Oct 27, 2026, 6:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Initial Investigation of [18F]P16-129 in Alzheimer's Disease Patients and Healthy Volunteers

NCT03902548
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[18F]P16-129
Drug
Lead sponsor
Five Eleven Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 27, 2026, 6:38 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of Neuroinflammation in Parkinson's Disease Using 18F-NOS PET/CT

NCT04062526
View directory record Official record
Conditions
Parkinson Disease, Healthy Volunteer
Interventions
[18F]NOS
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 27, 2026, 6:38 PM EDT
Recruiting Phase 2 Interventional

Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial

NCT06067269
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8
Interventions
Apalutamide, Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide, Guided Stereotactic Body Radiation Therapy, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration
Drug · Procedure · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 27, 2026, 6:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Glutamate-Glutamine Cycling (VCYC) During Cocaine Abstinence Using 1H-MRS

NCT02124941
View directory record Official record
Conditions
Cocaine Dependence, Healthy
Interventions
N-acetyl cysteine, [18F]FDG PET scan, 1H MRS, [11C]APP311 PET scan
Drug · Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 27, 2026, 6:38 PM EDT
Recruiting Phase 4 Interventional

Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech

NCT01818661
View directory record Official record
Conditions
PPA, Non-fluent Aphasia, Apraxia of Speech, Primary Progressive Non-fluent Aphasia, Primary Progressive Aphasia
Interventions
AV-1451
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 27, 2026, 6:38 PM EDT
Not listed Phase 2 Interventional

Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies

NCT05013099
View directory record Official record
Conditions
Melanoma, Merkel Cell Carcinoma, Unspecified, Renal Cell Carcinoma, Non Small Cell Lung Cancer
Interventions
zirconium Zr 89 crefmirlimab berdoxam
Biological
Lead sponsor
ImaginAb, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Little Rock, Arkansas • Duarte, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Oct 27, 2026, 6:38 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

CRF - Nociceptin Receptor Interactions

NCT03302416
View directory record Official record
Conditions
Healthy
Interventions
Hydrocortisone, [C-11]NOP-1A
Drug · Radiation
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 40 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 27, 2026, 6:38 PM EDT
Recruiting Phase 1Phase 2 Interventional

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

NCT03128034
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Myeloid Leukemia, Refractory Mixed Phenotype Acute Leukemia, Mixed Phenotype Acute Leukemia
Interventions
Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Pretargeted Radioimmunotherapy, Total-Body Irradiation, Biospecimen Collection, Single Photon Emission Computed Tomography
Drug · Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 27, 2026, 6:38 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

NCT02649985
View directory record Official record
Conditions
Multiple Sclerosis, Alzheimer's Disease
Interventions
[F-18]PBR06, [C-11]PBR28
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 27, 2026, 6:38 PM EDT
Active, not recruiting Early Phase 1 Interventional

Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer

NCT05141643
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
PET Scan
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 27, 2026, 6:38 PM EDT
Suspended Phase 2 Interventional

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

NCT06200103
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Clinical Observation, Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Questionnaire Administration, Single Photon Emission Computed Tomography
Procedure · Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 27, 2026, 6:38 PM EDT